# Fluid Therapy Guidelines for Dogs and Cats: A Practical Update ## Key Takeaways - Fluid therapy is reframed as a drug prescription, necessitating precise indication, dose, and adverse effect considerations, with balanced isotonic crystalloids as the primary choice for resuscitation and rehydration due to their extracellular fluid approximation. - Patient assessment integrates physical examination, serial body weight trends, and point-of-care ultrasound to accurately determine volume status, perfusion adequacy, and hydration deficits across intravascular, interstitial, and intracellular compartments. - Resuscitation involves rapid, titrated boluses of isotonic crystalloids (10-15 mL/kg in dogs, 5-10 mL/kg in cats) administered over 10-15 minutes with reassessment after each, aiming to normalize perfusion parameters rather than achieve a fixed volume. - Rehydration addresses interstitial and intracellular deficits by administering calculated deficits over 4-24 hours, adjusted based on cardiovascular status, while maintenance fluid therapy replaces ongoing losses with balanced crystalloids, emphasizing lower rates than historically assumed, especially during anesthesia. - Monitoring is critical and includes serial body weight (gain >1-2% daily suggests retention), perfusion parameters (heart rate, pulse quality), urine output (1-2 mL/kg/hr), and laboratory values (electrolytes, PCV/TS), with early detection of fluid overload via weight gain and respiratory effort. - Special populations, particularly those with cardiac or renal disease, require conservative fluid prescriptions with slower rates and more frequent reassessment due to conflicting therapeutic needs and increased susceptibility to volume overload. --- Fluid therapy is among the most frequently administered interventions in small animal practice, yet it is also one of the most readily misused. The 2024 AAHA Fluid Therapy Guidelines reframe fluids as drugs, capable of both therapeutic benefit and iatrogenic harm across the intravascular, interstitial, and intracellular compartments. This article distills the current evidence-based framework for fluid prescription in dogs and cats, serving the practicing veterinarian who needs a practical update on patient assessment, fluid selection, rate planning, and monitoring. It answers the clinical question of how to move from a generic "fluids for everyone" approach to an individualized prescription that accounts for the patient's hemodynamic status, comorbidities, and response to therapy. Specific disease protocols are excluded, the focus is on the foundational principles that apply across clinical scenarios. The shift toward individualized fluid therapy reflects a growing recognition that fluid overload is an independent contributor to morbidity. The guidelines emphasize that the same volume of crystalloid that is appropriate for one patient may be harmful in another, particularly in the presence of cardiac or renal disease. This update therefore prioritizes repeated clinical reassessment over fixed formulas, and it integrates the principle that fluid requirements change continuously as the patient's condition evolves. ## At a Glance | Parameter | Clinical Decision | Guiding Principle | |---|---|---| | Patient assessment | Determine volume status, perfusion, and hydration | Combine physical examination, body weight trends, and point-of-care ultrasound | | Fluid selection | Choose crystalloid, colloid, or blood product | Match fluid composition to the compartment requiring support | | Resuscitation | Rapid, controlled volume expansion | Use small, titrated boluses with reassessment after each | | Rehydration | Replace interstitial and intracellular deficits | Calculate deficit, then administer over 4 to 24 hours | | Maintenance | Meet ongoing losses | Use balanced crystalloids with appropriate potassium content | | Monitoring | Detect fluid overload early | Track body weight, central venous pressure, and respiratory effort | | Anesthesia | Reduce fluid rates | Avoid routine high-rate maintenance during anesthesia | | Comorbidities | Adjust for cardiac or renal disease | Anticipate conflicting fluid and diuretic requirements | ## Fluid Compartments and the Rationale for Fluid Selection Body water distributes across the intracellular, interstitial, and intravascular spaces, with the capillary endothelium and cell membranes acting as dynamic barriers. Crystalloids distribute according to their sodium content: isotonic crystalloids expand the extracellular space, with roughly one quarter remaining in the intravascular compartment. Colloids and blood products exert oncotic pressure and preferentially expand the intravascular volume. Understanding this distribution is essential because the clinical indication determines which compartment must be targeted. A patient in hypovolemic shock needs intravascular expansion, whereas a patient with dehydration but stable perfusion needs interstitial and intracellular repletion. The 2024 AAHA guidelines describe fluid therapy as a drug prescription, requiring the same attention to indication, dose, and adverse effects as any pharmacologic agent. Balanced isotonic crystalloids remain the first-line choice for most resuscitation and rehydration scenarios because they approximate the electrolyte composition of extracellular fluid. Hypertonic saline and synthetic colloids have narrower indications, and their use requires specific justification based on the patient's pathophysiology. ## The Fluid Therapy Plan: Assessment and Prescription ### Initial Patient Assessment The fluid plan begins with a structured assessment of three distinct but related parameters: perfusion, hydration, and ongoing losses. Perfusion reflects the adequacy of cardiac output and tissue oxygen delivery, assessed through mucous membrane color, capillary refill time, heart rate, pulse quality, and mental status. Hydration reflects the status of the interstitial and intracellular spaces, assessed through skin turgor, mucous membrane moisture, and eye position. These parameters can diverge, and the clinician must identify which compartment is primarily affected. Body weight is the single most reliable objective measure of fluid balance, and serial weights should be obtained whenever possible. Point-of-care ultrasound of the caudal vena cava and lungs adds diagnostic precision, particularly in distinguishing hypovolemia from fluid overload in patients with equivocal examination findings. ### Calculating the Prescription The fluid prescription has three components: the deficit, the maintenance requirement, and ongoing losses. The deficit is estimated from the physical examination, with each percentage point of dehydration representing a fluid deficit of approximately 10 mL per kilogram of body weight. Maintenance requirements cover insensible losses and urine output, and they vary with the patient's metabolic rate and clinical condition. Ongoing losses from vomiting, diarrhea, or third-space sequestration must be estimated and added to the plan. The guidelines caution against rigid adherence to calculated rates. Every estimate carries error, and the patient's response to therapy is the ultimate arbiter of whether the rate is appropriate. Reassessment intervals should be specified in the plan, and the rate adjusted accordingly. ## Resuscitation, Rehydration, and Maintenance ### Resuscitation Resuscitation is the rapid correction of life-threatening hypovolemia. The goal is to restore perfusion without inducing fluid overload. The 2024 AAHA guidelines recommend small, titrated boluses of isotonic crystalloids, typically 10 to 15 mL per kilogram in dogs and 5 to 10 mL per kilogram in cats, administered over 10 to 15 minutes with reassessment after each bolus. Cats are particularly susceptible to volume overload, and their smaller circulatory reserve demands a more conservative approach. The resuscitation phase ends when perfusion parameters normalize, not when a predetermined volume has been infused. ### Rehydration Rehydration addresses the interstitial and intracellular deficits that characterize dehydration. The calculated deficit is administered over 4 to 24 hours, depending on the patient's cardiovascular status and the urgency of correction. Rapid rehydration is appropriate for a dehydrated patient with normal perfusion, whereas a patient with concurrent cardiac disease requires slower correction to avoid volume overload. The route of administration, intravenous or subcutaneous, depends on the severity of dehydration and the patient's ability to absorb fluid from the subcutaneous space. ### Maintenance Maintenance therapy replaces ongoing losses in patients that cannot drink or that have increased losses. Balanced crystalloids with potassium supplementation are preferred, as maintenance requirements include obligate electrolyte losses. The guidelines emphasize that maintenance rates are lower than many practitioners assume, and that routine administration of high-rate maintenance fluids to anesthetized patients is no longer recommended. ## Monitoring and Adjustment Fluid therapy is a dynamic process, and the monitoring plan is as important as the initial prescription. Body weight should be measured at least twice daily in hospitalized patients, with an increase of more than 1 to 2 percent per day suggesting fluid retention. Respiratory rate and effort, lung auscultation, and peripheral edema are clinical indicators of volume overload. Central venous pressure monitoring is reserved for patients with tenuous cardiovascular status, and its interpretation requires consideration of ventricular compliance and intrathoracic pressure. The guidelines recommend scheduled reassessment points at which the clinician evaluates perfusion, hydration, body weight, and electrolyte status, then adjusts the rate and composition of fluids accordingly. This iterative approach reduces the risk of both under-resuscitation and fluid overload, and it aligns with the principle that fluids are drugs requiring dose titration. ## Special Populations and Comorbidities ### Cardiac and Renal Disease The coexistence of cardiac and renal disease in cats presents a particular challenge, as the management of one condition may conflict with the other. Parenteral fluid therapy for kidney disease aims to maintain mean arterial pressure and renal blood flow, whereas diuretics are necessary to reduce capillary hydrostatic pressure in heart failure. Overly aggressive volume expansion can precipitate or worsen congestive heart failure, while overly aggressive volume reduction can compromise renal perfusion. The clinician must therefore identify the dominant clinical problem, set explicit hemodynamic targets, and monitor both organ systems throughout therapy. The feline comorbidities literature emphasizes that the presence of heart disease should prompt a more conservative fluid prescription, with slower rates and more frequent reassessment. ### Anesthetized Patients Anesthesia alters cardiovascular compensation and reduces the patient's ability to handle fluid loads. The 2024 AAHA guidelines reiterate the recommendation for reduced fluid rates in anesthetized patients, with the goal of maintaining vascular access instead of providing aggressive volume expansion. Hypotension during anesthesia is better managed with vasopressors and small fluid boluses than with high-rate maintenance fluids, which risk interstitial edema and pulmonary complications. ## Uncertainties and Limitations The evidence base for veterinary fluid therapy remains limited by a relative scarcity of large, prospective, randomized trials. Many recommendations derive from human medicine, expert consensus, and physiologic first principles instead of species-specific outcome data. The optimal resuscitation fluid, the role of colloids, and the ideal monitoring strategy in specific disease states remain areas of active investigation and legitimate disagreement. The guidelines acknowledge these gaps and encourage clinicians to apply the framework with attention to individual patient response instead of adherence to fixed protocols. ## Choosing the Fluid: Crystalloids, Colloids, and Balanced Solutions The selection of a resuscitation or replacement fluid rests on the patient's acid-base status, electrolyte profile, and the presumed cause of volume deficit. Balanced crystalloids, such as lactated Ringer's solution or Plasma-Lyte, approximate extracellular fluid composition and remain the first-line choice for most dogs and cats requiring volume expansion. Normal saline (0.9% NaCl) is reserved for specific scenarios: hyponatremia requiring slow correction, metabolic alkalosis with volume depletion, or as a carrier for concurrent blood product administration. The 2024 AAHA guidelines emphasize that no single fluid suits every patient and that the prescription must be individualized after assessment of the fluid spaces [2024 AAHA Fluid Therapy Guidelines for Dogs and Cats](https://pubmed.ncbi.nlm.nih.gov/38885492/). Colloids, including synthetic starches and natural products such as albumin, exert greater oncotic pressure per unit volume than crystalloids. Their use has contracted substantially in recent years. Synthetic hydroxyethyl starches are associated with acute kidney injury and coagulopathy in critically ill human patients, and extrapolation of this risk to dogs and cats has led most veterinary consensus documents to recommend against their routine use. When colloid support is deemed necessary, the decision should be documented with a stated rationale, a defined endpoint, and a plan for discontinuation. Blood products, not synthetic colloids, are the appropriate volume expanders in patients with confirmed anemia or coagulopathy. The distinction between replacement and maintenance solutions matters clinically. Replacement fluids have sodium concentrations near 130 to 154 mEq/L and are designed to correct deficits. Maintenance fluids contain 40 to 60 mEq/L of sodium and are intended only to match ongoing losses in patients who cannot drink. Administering maintenance fluids to a hypovolemic patient fails to expand the intravascular space effectively. Administering replacement fluids at maintenance rates to a patient with normal renal function risks hypernatremia and volume overload. | Fluid Category | Examples | Sodium (mEq/L) | Primary Indication | Contraindications and Cautions | |---|---|---|---|---| | Balanced crystalloid | Lactated Ringer's, Plasma-Lyte | 130 to 140 | Resuscitation, rehydration, ongoing losses | Hyperkalemia with LRS in some renal patients, monitor lactate in hepatic failure | | Normal saline | 0.9% NaCl | 154 | Hyponatremia, metabolic alkalosis, blood product co-administration | Hyperchloremic metabolic acidosis with large volumes, avoid in hypernatremia | | Maintenance | Normosol-M, Plasma-Lyte 56 | 40 to 60 | Patients unable to drink, ongoing sensible losses | Never use for resuscitation, risk of hyponatremia if used for deficit replacement | | Synthetic colloid | Hydroxyethyl starch | Variable | Rarely indicated, consider only when crystalloids fail and blood products unavailable | Acute kidney injury, coagulopathy, avoid in sepsis and renal disease | | Blood products | Packed RBCs, fresh frozen plasma | Variable | Anemia, coagulopathy, hypoproteinemia with hemorrhage | Crossmatch before transfusion, monitor for transfusion reactions | ## Administration Routes and Equipment Intravenous access is the standard for resuscitation and for any patient with hemodynamic instability. Peripheral catheters in the cephalic or saphenous veins suffice for most cases. Central venous access is reserved for patients requiring prolonged therapy, those with poor peripheral veins, or those needing central venous pressure monitoring. Intraosseous access is a reliable alternative in neonates, kittens, and critically ill patients with vascular collapse, and it should be placed without delay when peripheral access fails twice. Subcutaneous fluid administration has a narrow but legitimate role. It is appropriate for stable patients with mild dehydration who can absorb fluids from the interstitial space, and it is commonly used for maintenance support in chronic kidney disease. It is not appropriate for resuscitation, for patients with poor peripheral perfusion, or for those with coagulopathies. The volume administered subcutaneously is absorbed slowly, and repeated large volumes can cause discomfort and unpredictable absorption [2024 AAHA Fluid Therapy Guidelines for Dogs and Cats](https://pubmed.ncbi.nlm.nih.gov/38885492/). The choice of administration set affects rate accuracy. Macro-drip sets deliver 10 to 20 drops per milliliter and are suitable for rapid resuscitation. Micro-drip sets deliver 60 drops per milliliter and allow precise low-rate delivery in small patients. Fluid pumps are strongly recommended for continuous rate infusions in cats and small dogs, where even modest over-delivery can produce volume overload. In settings without pumps, the clinician must calculate drip rates carefully and recheck them at each monitoring interval. ## Monitoring Parameters and Their Interpretation Monitoring is the mechanism by which the fluid plan is adjusted, and it must be tied to specific, measurable endpoints. The 2024 AAHA guidelines structure monitoring around three domains: perfusion parameters, volume status, and laboratory values [2024 AAHA Fluid Therapy Guidelines for Dogs and Cats](https://pubmed.ncbi.nlm.nih.gov/38885492/). Perfusion parameters include heart rate, pulse quality, mucous membrane color, capillary refill time, and mentation. These respond within minutes to effective resuscitation. A patient whose heart rate normalizes, whose pulses strengthen, and whose mentation improves has achieved adequate perfusion, regardless of the calculated fluid deficit. Persistent tachycardia with weak pulses after a fluid bolus should prompt reassessment of the diagnosis, not simply another bolus. Volume status is assessed through body weight, urine output, central venous pressure when available, and lung auscultation. Body weight remains the most practical and sensitive indicator of net fluid balance. Serial weights should be recorded at least twice daily in hospitalized patients receiving fluids. Urine output should be measured in critically ill patients, ideally with a urinary catheter, and a falling output despite adequate perfusion suggests renal injury or obstruction. Laboratory monitoring includes packed cell volume, total solids, electrolytes, and acid-base status. These should be rechecked at intervals dictated by the patient's stability, not by a fixed schedule. A patient receiving large-volume resuscitation should have electrolytes measured within hours. A stable patient on maintenance fluids may only require daily checks. The development of tachyarrhythmias, weakness, or altered mentation during fluid therapy should trigger immediate electrolyte measurement. | Parameter | Frequency in Critical Patients | What It Detects | Action Threshold | |---|---|---|---| | Body weight | Every 4 to 6 hours | Net fluid balance, occult overload | Gain of more than 2% to 3% over 24 hours warrants diuretic consideration | | Heart rate and pulse quality | Every 15 to 30 minutes during resuscitation | Perfusion status, response to bolus | Persistent tachycardia after 2 boluses prompts diagnostic reassessment | | Urine output | Hourly if catheterized | Renal perfusion, adequacy of volume | Less than 1 to 2 mL/kg/hour over 4 hours requires investigation | | PCV and total solids | Every 4 to 8 hours during resuscitation | Hemodilution, ongoing hemorrhage | Falling PCV with instability suggests blood loss, also dilution | | Electrolytes | Every 6 to 12 hours during active correction | Iatrogenic derangements | Potassium outside reference range requires rate adjustment | | Lung auscultation | Every 4 hours | Volume overload, pulmonary edema | New crackles or increased respiratory effort mandates fluid reduction | ## Common Pitfalls and Their Prevention The most frequent error in fluid therapy is the administration of a calculated deficit without reassessment. The deficit is an estimate, and the patient's response is the only valid measure of accuracy. A second common error is the use of maintenance fluids for resuscitation, which fails to restore perfusion and may cause hyponatremia. A third is the failure to account for ongoing losses, including vomiting, diarrhea, polyuria, and third-space losses, which must be added to the maintenance requirement. Volume overload is an underappreciated complication. It manifests as weight gain, serous nasal discharge, chemosis, peripheral edema, and ultimately pulmonary edema. Cats are particularly susceptible, and their smaller body mass amplifies the effect of calculation errors. The 2024 AAHA guidelines stress that fluid therapy should be prescribed with the same care as any drug, including a defined dose, route, and discontinuation plan [2024 AAHA Fluid Therapy Guidelines for Dogs and Cats](https://pubmed.ncbi.nlm.nih.gov/38885492/). The guidelines also note that reduced fluid rates are recommended in anesthetized patients, where vasodilation and anesthetic-induced myocardial depression alter fluid requirements [2024 AAHA Fluid Therapy Guidelines for Dogs and Cats](https://pubmed.ncbi.nlm.nih.gov/38885492/). A final pitfall is the reflexive administration of fluids to every patient with hypotension. Hypotension may reflect sepsis, hemorrhage, cardiac failure, or drug effects, and the fluid response differs by cause. In patients with suspected cardiac disease, fluid administration must be cautious, and the interaction between volume status and cardiac function should be considered before any bolus is given [Feline comorbidities: cardiovascular and kidney diseases](https://pubmed.ncbi.nlm.nih.gov/41863293/). ## Documentation and Communication The fluid therapy plan should be documented as a prescription, not an afterthought. The medical record should state the fluid type, the rate, the route, the intended duration, and the monitoring parameters that will trigger adjustment. Each reassessment should be recorded with the patient's weight, perfusion parameters, and any changes made to the plan. This documentation serves clinical continuity and provides a defensible record of clinical reasoning. When the plan changes, the reason for the change should be stated explicitly. ## Recognized Complications and Early Detection Fluid therapy failure typically presents as one of four syndromes: under-resuscitation, fluid overload, electrolyte derangement, or route-associated injury. The 2024 AAHA guidelines frame fluids as drugs whose beneficial and harmful effects occur within the intravascular, interstitial, and intracellular spaces, which makes dose and rate errors clinically indistinguishable from adverse drug events [2024 AAHA Fluid Therapy Guidelines for Dogs and Cats](https://pubmed.ncbi.nlm.nih.gov/38885492/). Fluid overload is the most consequential failure mode. It develops when administration exceeds the patient's capacity to redistribute or excrete fluid, and it is detected earliest through body weight trends instead of physical examination. A gain of more than 10% over admission weight during resuscitation or rehydration warrants immediate rate reduction. Serial lung auscultation, jugular distension, and peripheral edema are later findings. In cats, tachypnea and a gallop rhythm or new murmur may precede audible crackles. Electrolyte complications arise from both the fluid chosen and the rate of correction. Rapid administration of potassium-containing fluids to a hyperkalemic patient, or aggressive sodium correction in a chronically hyponatremic patient, can produce arrhythmias or neurologic deterioration. Serial electrolyte measurement is the only reliable detection method, and sampling intervals should shorten as the magnitude of the baseline derangement increases. Route-associated complications include thrombophlebitis from peripheral catheters, extravasation injury, and catheter-related bloodstream infection. Daily catheter site inspection, limb circumference comparison, and documentation of catheter dwell time are the minimum monitoring standard. ## Common Errors and Corrective Action Less experienced clinicians most often err in the initial rate calculation. The most frequent mistake is treating the maintenance rate as a ceiling instead of a starting point, then failing to adjust when the patient's losses exceed the estimate. The corrective action is to re-estimate losses at each reassessment interval and to document the basis for any rate change. A second recurring error is the reflexive use of a single fluid type for all patients. Balanced crystalloids are appropriate for most resuscitation and rehydration, but the patient with concurrent cardiac and renal disease requires a plan that respects both organ systems, because therapies for one may conflict with the other [feline comorbidities and their impact on fluid management](https://pubmed.ncbi.nlm.nih.gov/41863293/). The corrective action is to identify comorbidities before writing the fluid order, not after a complication appears. A third error is discontinuing monitoring once the patient appears stable. The anesthetized patient is particularly vulnerable because anesthetic agents blunt compensatory responses, and the guidelines recommend reduced fluid rates in this population [AAHA/AAFP fluid therapy guidelines](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/). The corrective action is to maintain the same monitoring frequency during recovery as during the procedure itself. ## Troubleshooting Guide | Observation | Likely cause | Discriminating check | |---|---|---| | Weight gain >10% with tachypnea | Fluid overload | Lung auscultation, jugular distension, compare to admission weight | | Persistent tachycardia after resuscitation | Under-resuscitation or ongoing loss | Reassess perfusion parameters, quantify ongoing losses, check catheter patency | | New arrhythmia during fluid administration | Electrolyte derangement | Stat electrolyte panel, review fluid type and rate | | Limb swelling at catheter site | Extravasation or phlebitis | Remove catheter, compare limb circumference, inspect for heat or pain | | No urine output despite adequate perfusion | Renal injury or obstruction | Check bladder size, urinary catheter patency, measure blood pressure | ## Limitations of the Evidence The evidence base for veterinary fluid therapy is thinner than for human medicine. Most recommendations derive from expert consensus, physiologic first principles, and extrapolation from human critical care instead of from large randomized trials in dogs and cats. The 2024 AAHA guidelines acknowledge this by presenting recommendations as consensus guidance instead of as high-certainty directives [2024 AAHA Fluid Therapy Guidelines for Dogs and Cats](https://pubmed.ncbi.nlm.nih.gov/38885492/). Expert opinion still differs on several points. The choice between balanced crystalloids and saline in specific disease states remains contested. The role of colloids in resuscitation is debated, with some authorities advising against their routine use while others reserve them for defined rescue scenarios. Optimal fluid rates in anesthetized patients continue to shift downward, but the precise lower bound has not been established. Clinicians should expect these areas to evolve as new comparative data emerge. ## Referral, Consultation, and Reporting Referral or specialist consultation is warranted when the patient fails to respond to an appropriately calculated plan, when fluid overload develops despite adherence to monitoring protocols, or when the patient has concurrent cardiac and renal disease that complicates every fluid decision. In the latter group, early consultation with a cardiologist or nephrologist is preferable to attempting sequential management of each organ system in isolation [feline comorbidities and their impact on fluid management](https://pubmed.ncbi.nlm.nih.gov/41863293/). Laboratory involvement is indicated when electrolyte derangements are severe, when acid-base disturbances do not correct with initial therapy, or when the patient requires blood products. Serial blood gas and electrolyte panels should be obtained at intervals short enough to detect complications before they become clinically apparent. Regulatory reporting obligations vary by jurisdiction and practice setting. Clinicians should be familiar with local requirements for reporting adverse events associated with fluid administration, particularly when a product defect or contamination is suspected. Professional liability considerations favor thorough documentation of the fluid plan, the monitoring performed, and the clinical rationale for each adjustment, as these records constitute the primary defense if a complication is later questioned. ## Frequently Asked Questions ### How do I adapt fluid therapy when advanced monitoring equipment is unavailable? When direct blood pressure or central venous pressure monitoring is absent, rely on serial physical examination findings: mucous membrane color, capillary refill time, skin turgor, heart rate, pulse quality, and body weight. Urine output, when measurable, provides a practical index of perfusion. The 2024 AAHA guidelines emphasize that monitoring frequency and intensity should match patient stability, and that even basic parameters, tracked consistently, detect trends before decompensation occurs. Recheck body weight at least twice daily in hospitalized patients receiving fluids. A gain exceeding 10 percent of administered volume suggests fluid retention. When uncertainty persists, choose the lower end of the estimated rate range and reassess sooner instead of later. ### What fluid strategy is reasonable when cost limits hospitalization or intensive monitoring? Outpatient or shortened protocols may be appropriate for stable patients with mild deficits. Subcutaneous fluid administration can support rehydration when oral intake is inadequate and the deficit is modest, provided the patient has no contraindications such as severe hypovolemia, coagulopathy, or peripheral edema. The [2024 AAHA Fluid Therapy Guidelines for Dogs and Cats](https://pubmed.ncbi.nlm.nih.gov/38885492/) describe subcutaneous delivery as suitable for maintenance support in selected cases, but not for resuscitation. If the owner cannot afford hospitalization, discuss the trade-off between reduced monitoring and higher risk explicitly. Document the plan, the anticipated risks, and the owner's informed decision. For patients requiring ongoing care at home, teach owners to record daily weight, appetite, and urine output, and schedule a revisit within 24 to 48 hours. ### How should I document the fluid therapy plan and its adjustments? Record the problem list, the estimated deficit, maintenance requirements, ongoing losses, and the chosen fluid type, rate, and route at the time of prescription. Note the patient's body weight at baseline and at each reassessment. Document every rate change with the clinical reason, the time of the change, and the clinician responsible. The [AAHA/AAFP fluid therapy guidelines](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/) recommend that the medical record reflect both the intended plan and the actual response, including any complications such as vomiting, dyspnoea, or venous catheter complications. Include a stop or reassessment time for every fluid order. This practice prevents unintended prolonged administration and supports continuity when shifts change. ### How do I explain a fluid therapy complication to a concerned owner? Describe the complication in plain terms, state what has been done to address it, and outline the revised plan. For example, if volume overload develops, explain that the patient received more fluid than the body could accommodate, that diuretics or a reduced rate have been started, and that monitoring will be intensified. Avoid defensive language and do not minimize the event. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides useful background on fluid balance disorders that can help you frame the explanation accurately. Acknowledge uncertainty when the cause is not fully clear. Offer the owner a specific time for the next update. Document the conversation, including the owner's questions and your responses, in the medical record. ### When should I stop fluid therapy instead of continue at a reduced rate? Discontinue fluids when the patient meets maintenance needs through voluntary intake and shows stable body weight, normal hydration parameters, and adequate urine output. For patients with cardiac or renal comorbidity, the decision to stop is as deliberate as the decision to start. The [feline comorbidities review](https://pubmed.ncbi.nlm.nih.gov/41863293/) notes that volume expansion intended to support renal perfusion can stress a failing heart, so reassess the indication for ongoing fluids at least daily in these patients. If the original indication was resuscitation, stop once perfusion parameters normalize. If the indication was rehydration, stop when deficits are corrected and oral intake is reliable. Do not taper fluids purely for convenience, either the indication persists or it does not. ### How do fluid therapy principles translate to species outside dogs and cats? The same physiological framework applies, but species-specific differences in body composition, renal physiology, and common diseases alter the prescription. In swine production, for example, individual patient assessment is rarely feasible, and population-level strategies such as oral fluid-based surveillance are used to detect disease and guide group-level interventions, as described in the [guidelines for oral fluid-based surveillance of viral pathogens in swine](https://pubmed.ncbi.nlm.nih.gov/33082999/). For exotic or production species, consult species-specific references and consider that drug withdrawal periods and legal requirements for treatment records vary by jurisdiction. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) address health management expectations relevant to food animals. When in doubt, seek advice from a colleague with species expertise before prescribing. ## Related Clinical & Scientific Guides * [Toxicology in Emergency Practice: Common Poisons and Diagnostic Approach](/knowledge/veterinary-medicine/emergency-critical-care/toxicology-emergency-practice-common-poisons-diagnostic-approach) * [Veterinary Cardiopulmonary Resuscitation: Post-Cardiac Arrest Care](/knowledge/veterinary-medicine/emergency-critical-care/veterinary-cardiopulmonary-resuscitation-post-cardiac-arrest-care) * [Veterinary Blood Transfusion Reactions: Recognition and Management](/knowledge/veterinary-medicine/emergency-critical-care/veterinary-blood-transfusion-reactions-recognition-management) ## References and Further Reading - [Beyond guidelines: what do I need to know when dealing with fungal diagnostics?](https://pubmed.ncbi.nlm.nih.gov/40716569/). 2025. - [Guidelines for oral fluid-based surveillance of viral pathogens in swine.](https://pubmed.ncbi.nlm.nih.gov/33082999/). 2020. - [2024 AAHA Fluid Therapy Guidelines for Dogs and Cats.](https://pubmed.ncbi.nlm.nih.gov/38885492/). 2024. - [A practical guide for small bowel transplantation in rats-review of techniques and models.](https://pubmed.ncbi.nlm.nih.gov/28601304/). 2017. - [Feline comorbidities: cardiovascular and kidney diseases.](https://pubmed.ncbi.nlm.nih.gov/41863293/). 2026. - [Evidence-Based Clinical Management of Canine Cognitive Dysfunction Syndrome: Diagnostic Algorithms, Practical Guidelines, Critical Appraisal of Biomarkers and Translational Limitations.](https://pubmed.ncbi.nlm.nih.gov/41976093/). 2026. - [RECOVER Initiative Veterinary CPR Guidelines](https://recoverinitiative.org/). Veterinary Emergency and Critical Care Society. - [AAHA/AAFP Fluid Therapy Guidelines for Dogs and Cats](https://www.aaha.org/resources/2024-aaha-fluid-therapy-guidelines-for-dogs-and-cats/). AAHA. - [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual. ## Related Articles - [Subcutaneous Fluid Therapy in Dogs: Indications, Volumes, and Monitoring](/knowledge/veterinary-medicine/emergency-critical-care/subcutaneous-fluid-therapy-dogs-indications-volumes-monitoring) - [Veterinary Fluid Therapy: Crystalloids vs Colloids](/knowledge/veterinary-medicine/emergency-critical-care/veterinary-fluid-therapy-crystalloids-colloids) - [Blood Transfusion in Dogs and Cats: Crossmatching and Compatibility](/knowledge/veterinary-medicine/emergency-critical-care/blood-transfusion-dogs-cats-crossmatching-compatibility) - [Electrolyte Emergencies in Dogs and Cats: Recognition and Correction](/knowledge/veterinary-medicine/emergency-critical-care/electrolyte-emergencies-dogs-cats-recognition-correction) - [RECOVER CPR Guidelines: Updates and Practical Implementation](/knowledge/veterinary-medicine/emergency-critical-care/recover-cpr-guidelines-updates-practical-implementation) > This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.